Product Description
Mechanisms of Action: APP Modulator, Tau Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Amyloid Solution Inc
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: South Korea
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Alzheimer Disease|Cognitive Dysfunction
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06786676 |
AS-S603-P101 | P1 |
Recruiting |
Alzheimer Disease|Cognitive Dysfunction |
2026-12-31 |
50% |
2026-05-12 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|